Region Business Director - Mid Atlantic

The role

The Region Business Director will lead the strategic launch for Corcept's entry to the oncology commercial market. This leader will manage a sales team and align strategic plans to maximize individual and team accountabilities.

What you will do

• Cultivate a high trust culture that inspires excellence and puts people first
• Collaborate with cross-functional leaders to develop brand and sales strategies
• Lead the execution of strategies to drive revenue growth and market share
• Work with leadership to lead recruitment, development, and retention of talent
• Execute post-launch plans to drive product adoption and market performance
• Establish sales goals and monitor performance against targets
• Identify and prioritize key accounts including oncologists, hospitals, and cancer treatment centers
• Build and maintain relationships with key opinion leaders and healthcare professionals
• Conduct market analysis to understand regional trends and customer needs
• Collaborate with marketing and medical affairs to ensure consistent messaging

Required qualifications

• Proven track record of launching teams and products into the Oncology market

Nice to have

• Proven experience in successfully launching key products/brands in the oncology field
• Track record in launching and managing sales of oncology products, particularly in the GYN/ONC therapeutic area
• Previous success building and leading high-performing teams
• Inspirational leadership style with the ability to motivate and encourage accountability
• Strategic thinker with a strong business acumen and the ability to translate strategy into actionable sales plans
• Bachelor’s degree plus 10+ years of commercial experience in pharmaceuticals
• Extensive understanding and experience in both clinical aspects and business of oncology, with a focus on gyne/onc
• In-depth understanding of U.S. payer and market access dynamics

About the company

Corcept is focused on the science of cortisol. The company has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists.